Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence-Reference-Cited by-同舟云学术

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

Published:2022-02 Issue: Volume:100 Page:103492
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Farrell Michael,Shahbazi Jeyran,Byrne Marianne,Grebely Jason,Lintzeris Nicholas,Chambers Mark,Larance Briony,Ali Robert,Nielsen Suzanne,Dunlop Adrian,Dore Gregory J.,McDonough Michael,Montebello Mark,Nicholas Thomas,Weiss Rob,Rodgers Craig,Cook Jon,Degenhardt Louisa

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference36 articles.

1. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study;Albayaty;Advances in Therapy,2017

2. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research;Amato;Journal of Substance Abuse Treatment,2005

3. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-Month safety, tolerability, and efficacy analysis;Andorn;Journal of Clinical Psychopharmacology,2020

4. The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: A 15-year retrospective cohort study;Bharat;Addiction,2021

5. Model selection and Akaike’s information criterion (AIC): The general theory and its analytical extensions;Bozdogan;Psychometrika,1987

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients’ Interpersonal Relationships during the First Year of Treatment;Substance Use & Misuse;2024-08-20

2. An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products;Journal of Substance Use and Addiction Treatment;2024-07

3. ‘Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study;International Journal of Drug Policy;2024-07

4. Adherence to buprenorphine-XR through hybrid telehealth contingency management procedures: a case series;Journal of Substance Use;2024-05-09

5. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial;International Journal of Drug Policy;2024-05